
Sign up to save your podcasts
Or


Dr Keith Chappell discusses the bivalent recombinant vaccine for COVID-19 following the study by Dayan and colleagues, with focus on vaccine access, variants and boosters, tolerability and side effects, as well as hopes for future trials.
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
By The Lancet Group5
11 ratings
Dr Keith Chappell discusses the bivalent recombinant vaccine for COVID-19 following the study by Dayan and colleagues, with focus on vaccine access, variants and boosters, tolerability and side effects, as well as hopes for future trials.
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

320 Listeners

497 Listeners

2 Listeners

37 Listeners

366 Listeners

22 Listeners

0 Listeners

0 Listeners

2 Listeners

1 Listeners

0 Listeners

0 Listeners

0 Listeners

16,083 Listeners

1 Listeners

1 Listeners

0 Listeners

1 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners

909 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners